Research programme: NMDA receptor modulators - Novartis
Latest Information Update: 01 Feb 2021
Price :
$50 *
At a glance
- Originator Cadent Therapeutics; Jubilant Biosys
- Developer Novartis
- Class Antidepressants; Small molecules
- Mechanism of Action NR2B N Methyl D Aspartate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders